Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age. 12-80~* Documented physician-diagnosed asthma for at least 12 months~* Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.~* Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.~* At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.~* Morning pre-BD FEV1 \<80% predicted normal (\<90% for subjects 12-17 yrs)~* Evidence of asthma as documented by either: Documented historical reversibility of FEV1 ≥12% and ≥200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol) reversibility of FEV1 ≥12% and ≥200 mL during screening.~* Documented history of at least 2 asthma exacerbation events within 12 months.~* ACQ-6 score ≥1.5 at screening and on day of randomization~Exclusion Criteria:~* Pulmonary disease other than asthma.~* History of cancer.~* History of a clinically significant infection.~* Current smokers or subjects with smoking history ≥10 pack-years and subjects using vaping products, including electronic cigarettes.~* History of chronic alcohol or drug abuse within 12 months.~* Hepatitis B, C or HIV.~* Pregnant or breastfeeding.~* History of anaphylaxis following any biologic therapy.~* Subject randomized in the current study or previous tezepelumab studies.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Tezepelumab: Tezepelumab subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: Placebo subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).